BR reports fiscal Q4 results on August 4 with options positioning at its most bullish in months — a notable contrast to cautious sentiment that dominated much of the summer.
The clearest positioning signal is in options. The put/call ratio has dropped to 0.72, more than 1.2 standard deviations below its 20-day average of 1.07, and near the lowest level of the past year. That means calls are heavily outweighing puts — traders are buying upside exposure rather than downside protection. The shift is striking: through most of June and early July, the PCR ran consistently above 1.3, so this rotation toward calls is recent and deliberate. The stock has backed that optimism up, gaining 12% over the past month to close at $153.95, with a 3.4% rise on the week alone.
Short interest is elevated but not aggressive. Bears hold about 3.5% of the free float — up roughly 16% over the past month — yet the lending market is relaxed. Borrow availability is extremely loose at over 7,500%, meaning roughly 26 shares remain available to borrow for every one currently lent out. Cost to borrow has actually fallen 12% over the past week to just 0.30%, a historically low rate. The ORTEX short score holds at a modest 35, well below levels associated with squeeze risk. The picture is one of incremental hedging, not a concentrated bear thesis.
The bull-bear debate heading into the print centers on growth momentum versus margin caution. Bulls point to recurring revenue running above $1 billion — up over 9% year-on-year — and closed sales growth of 24%, alongside a long-term UBS Wealth Management partnership that underpins forward visibility. EPS momentum ranks in the 92nd percentile on a 30-day basis, and the 85th percentile over 90 days, suggesting estimates have been moving up. Bears flag a 27% decline in event-driven revenue and flat adjusted operating margins guided at 20-21%, which limits the case for meaningful profitability expansion. Analyst activity from the most recent earnings cycle in May was uniformly cautious on price targets — targets were cut across the board by DA Davidson, UBS, RBC Capital, and others — though all maintained their ratings. That analyst data is now nearly three months old, and the stock at $153.95 trades well below the consensus target of around $206, leaving a gap that the print could either close or entrench.
One note on CEO activity: Tim Gokey purchased just over $1 million of stock in early March at roughly $194, well above where the stock trades today. That on-market buy preceded a period of weakness, and the stock has not recovered to those levels. It is worth noting that the net insider position over 90 days reflects net buying, though recent activity has been modest award-related transactions.
Among correlated peers, the week has been broadly positive — EXLS surged 23%, G and PAYC both gained around 12-13%, and ADP added 6.5% — suggesting sector tailwinds that BR's own 3.4% weekly gain has not fully captured. After the two most recent prior prints, the stock fell 3-4% on the day and extended losses over five days. The August 4 report is therefore a test of whether the bullish options rotation and sector momentum can overcome a recent pattern of post-earnings selling.
See the live data behind this article on ORTEX.
Open BR on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
